Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).

Antimicrobial agents and chemotherapy - 1 Feb 2009

Flint Mike, Mullen Stanley, Deatly Anne M, Chen Wei, Miller Lynn Z, Ralston Robert, Broom Colin, Emini Emilio A, Howe Anita Y M

Abstract excerpt

HCV-796 is a nonnucleoside inhibitor of the hepatitis C virus (HCV) nonstructural protein 5B (NS5B) polymerase, and boceprevir is an inhibitor of the NS3 serine protease. The emergence of replicon variants resistant to the combination of HCV-796 and boceprevir was evaluated. Combining the inhibit...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzofurans
Share to Electroporation
Share to Interferons

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Nucleic Acid Synthesis Inhibitors

Share to Proline

Share to Protease Inhibitors

Share to Replicon

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 18936191
DOI: 10.1128/AAC.01081-08
PMCID: PMC2630598

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18936191-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).PMID 18936191Read ↗

A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors.Semantic proximity Read ↗

Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro.Semantic proximity Read ↗

Selection of replicon variants resistant to ACH-806, a novel hepatitis C virus inhibitor with no cross-resistance to NS3 protease and NS5B polymerase inhibitors.Semantic proximity Read ↗

Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro.Semantic proximity Read ↗

Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052.Semantic proximity Read ↗

Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796.Semantic proximity Read ↗

Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations.Semantic proximity Read ↗

Selecting and characterizing drug-resistant hepatitis C virus replicon.Semantic proximity Read ↗

Studies on hepatitis C virus resistance to inhibitors in replicon systems.Semantic proximity Read ↗

Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus.Semantic proximity Read ↗

Identification of hepatitis C virus NS5A inhibitors.Semantic proximity Read ↗

The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.